Dr. Rita Hocog Inos Territorial Fellowship Act
Legislative Progress
Introduced
February 5, 2013
Latest Action
February 13, 2013
Primary Sponsor
Gregorio Kilili Camacho SablanDemocratic(MP)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
47pct
8d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2016 · fourth_quarter · Medicare/Medicaid
Medicare Coverage and Reimbursement issues, including the CMS Part B Drug Demonstration Proposed Rule; Medicare access to DXA services, including HR 2461, and legislative issues related to the CMS 2017 Hospital Outpatient Prospective Payment proposed rule; Medicare reimbursement for antimicrobial drugs, including related provisions in HR 512, The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014.
Client expense: Not reported · Firm income: $30,000
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
Medicare Coverage and Reimbursement issues, including the CMS Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Medicare reimbursement for antimicrobial drugs, including related provisions in HR 512, The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Medicare Coverage and Reimbursement issues, including the CMS Part B Drug Demonstration Proposed Rule; Medicare access to DXA services, including HR 2461, and legislative issues related to the CMS 2017 Hospital Outpatient Prospective Payment proposed rule; Medicare reimbursement for antimicrobial drugs, including related provisions in HR 512, The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
Medicare Coverage and Reimbursement issues, including the CMS Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Medicare reimbursement for antimicrobial drugs, including related provisions in HR 512, The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model Medicaid Program: Covered Outpatient Drugs (CMS-2345-FC) - Provisions related to line extension drug definition, effective date and other issues S. 31: Medicare Prescription Drug Price Negotiation Act of 2015 - Provisions related to Secretary negotiation authority in Part D program S. 141: Protecting Seniors' Access to Medicare Act of 2015 - Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 - Provisions related to the reauthorization of the national controlled substance monitoring program S. 648: Medicare Formulary Improvement Act of 2015 - Provisions related to codification of six protected classes in Part D program S. 1083: Medicare Drug Savings Act of 2015 - Provisions related to drug rebates in Medicare Part D S. 1913: Stopping Medication Abuse and Protecting Seniors Act of 2015 - Provisions related to programs to prevent prescription drug abuse under the Medicare program S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures S. 2646: Veterans Choice Improvement Act of 2016 - Provisions related to TRICARE drug pricing S. 2981: A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes H.R. 22: FAST Act - Medicare related offsets to the biopharmaceutical industry HR. 512 - the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 - Provisions related to IPAB repeal H.R. 2005: Medicare Drug Savings Act of 2015 - Provisions related to changes to Part D rebates H.R. 2298: Medicare Patient Safety and Drug Abuse Prevention Act - Provisions related to the design of a Part D Lock-in program H.R. 3513: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model H.R. 5273: Helping Hospitals Improve Patient Care Act of 2016 - Provisions related to exemption of hospitals that had off-site facilities under development Other: - Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed rules [CMS-2390-P] - Provisions related to Medicaid - Proposed Medicare hospital outpatient prospective payment system (OPPS) rule for 2016 (CMS-1633-P) - Proposed Medicare physician fee schedule (MPFS) rule for 2016 (CMS-1631-P) - Department of Health and Human Services (HHS) delivery system reform issues and regulatory barriers to innovation - Medicare Part B Average Sales Price (ASP) policy issues - Medicare Part D rebates policy issues - Drug cost and pricing policy issues - Transparency policy issues - Medication adherence policy issues - Alternative payment models policy issues - Value-based arrangements policy issues - Coding and reimbursement policy issues including for biologics - Center for Medicare and Medicaid Innovation (CMMI) transparency policy issues - MedPAC June Report - Part B and D policy issues - Medicaid rebates/reformulations policy issues - Non-interference policy issues
Client expense: $1,070,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2016 · first_quarter · Medicare/Medicaid
Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 8, 2016) - Provisions related to the Medicare Part B Drug Payment Model Medicaid Program: Covered Outpatient Drugs (CMS-2345-FC) - Provisions related to line extension drug definition, effective date and other issues S. 31: Medicare Prescription Drug Price Negotiation Act of 2015 - Provisions related to Secretary negotiation authority in Part D program S. 141: Protecting Seniors' Access to Medicare Act of 2015 - Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 275: Medicare Home Infusion Site of Care Act of 2015 - Provisions related to Medicare coverage S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 - Provisions related to the reauthorization of the national controlled substance monitoring program S. 648: Medicare Formulary Improvement Act of 2015 - Provisions related to codification of six protected classes in Part D program S. 1083: Medicare Drug Savings Act of 2015 - Provisions related to drug rebates in Medicare Part D S. 1253: Patient Access to Disposable Medical Technology Act of 2015 - Provisions related to capitated payments for disposable medical technology S. 1396: Value-Based Insurance Design Seniors Copayment Reduction Act of 2015 - Provisions related to changes to the Medicare Advantage Program S. 1884: Medicare Prescription Drug Savings and Choice Act of 2015 - Provisions related to the Medicare Operated Prescription Drug Plan Option S. 1913: Stopping Medication Abuse and Protecting Seniors Act of 2015 - Provisions related to programs to prevent prescription drug abuse under the Medicare program S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures S. 2409: Medicare and Medicaid Improvements and Adjustments Act of 2015 - Provisions related to outpatient reimbursement rates S. 2646: Veterans Choice Improvement Act of 2016 - Provisions related to TRICARE drug pricing H.R. 22: FAST Act - Medicare related offsets to the biopharmaceutical industry HR. 512 - the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 - Provisions related to IPAB repeal H.R. 2005: Medicare Drug Savings Act of 2015 - Provisions related to changes to Part D rebates H.R. 2298: Medicare Patient Safety and Drug Abuse Prevention Act - Provisions related to the design of a Part D Lock-in program H.R. 3513: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures H.R. 4273: Medicare and Medicaid Improvements and Adjustments Act of 2015 - Provisions related to outpatient reimbursement rates Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed rules [CMS-2390-P] - Provisions related to Medicaid Proposed Medicare hospital outpatient prospective payment system (OPPS) rule for 2016 (CMS-1633-P) Proposed Medicare physician fee schedule (MPFS) rule for 2016 (CMS-1631-P) Hospital Improvements for Payment Act (discussion draft) - Provisions related to Medicare Parts A and B reform Department of Health and Human Services (HHS) delivery system reform issues and regulatory barriers to innovation Medicare Part B Average Sales Price (ASP) policy issues Medicare Part D rebates policy issues Drug cost and pricing policy issues Transparency policy issues Medication adherence policy issues Alternative payment models policy issues Value-based arrangements policy issues Coding and reimbursement policy issues including for biologics Center for Medicare and Medicaid Innovation (CMMI) transparency policy issues Chronic Care Working Group - Medicare policy affecting drugs
2016 · first_quarter · Medicare/Medicaid
Medicare Coverage and Reimbursement issues; Medicare access to DXA services; Medicare reimbursement for antimicrobial drugs, including related provisions in HR 512, The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014.
Client expense: Not reported · Firm income: $90,000
2015 · fourth_quarter · Medicare/Medicaid
S. 31: Medicare Prescription Drug Price Negotiation Act of 2015 - Provisions related to Secretary negotiation authority in Part D program S. 141: Protecting Seniors' Access to Medicare Act of 2015 - Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 275: Medicare Home Infusion Site of Care Act of 2015 - Provisions related to Medicare coverage S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 - Provisions related to the reauthorization of the national controlled substance monitoring program S. 648: Medicare Formulary Improvement Act - Provisions related to codification of six protected classes in Part D program S. 1083: Medicare Drug Savings Act of 2015 - Provisions related to drug rebates in Medicare Part D S. 1253: Patient Access to Disposable Medical Technology Act of 2015 - Provisions related to capitated payments for disposable medical technology S. 1396: Value-Based Insurance Design Seniors Copayment Reduction Act of 2015 - Provisions related to changes to the Medicare Advantage Program S. 1884: Medicare Prescription Drug Savings and Choice Act of 2015 - Provisions related to the Medicare Operated Prescription Drug Plan Option S. 1913: Stopping Medication Abuse and Protecting Seniors Act of 2015 - Provisions related to programs to prevent prescription drug abuse under the Medicare program S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures H.R. 22: FAST Act - Medicare related offsets to the biopharmaceutical industry H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 - Provisions related to IPAB repeal H.R. 2005: Medicare Drug Savings Act of 2015 - Provisions relating to changes to Part D rebates H.R. 2298: Medicare Patient Safety and Drug Abuse Prevention Act - Provisions related to the design of a Part D Lock-in program H.R. 3513: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures H.R. 3819: Surface Transportation Extension Act of 2015 - Medicare related offsets to the biopharmaceutical industry H.R. __, S. __: Medicare and Medicaid Improvements and Adjustments Act of 2015 - Provisions related to Hospital Outpatient Department (HOPD) reimbursement rates Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed Rules [CMS-2390-P] - Provisions related to Medicaid Medicaid Program; Covered Outpatient Drugs; Proposed Rule [CMS-2345-F] - Provisions related to calculating Average Manufacturer Price (AMP) Proposed Medicare hospital outpatient prospective payment system (OPPS) rule for 2016 (CMS-1633-P) Proposed Medicare physician fee schedule (MPFS) rule for 2016 (CMS-1631-P) Hospital Improvements for Payment Act (discussion draft) - Provisions related to Medicare Parts A and B reform Department of Health and Human Services (HHS) delivery system reform issues and regulatory barriers to innovation Medicare Part B Average Sales Price (ASP) policy issues Medicare Part D rebates policy issues Drug cost and pricing policy issues Transparency policy issues Medication adherence policy issues Alternative payment models policy issues Chronic Care Working Group - Medicare policy affecting drugs HR. 512 - the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
2015 · fourth_quarter · Medicare/Medicaid
Medicare Coverage and Reimbursement issues; Medicare access to DXA services; Medicare reimbursement for antimicrobial drugs, including related provisions in HR 512, The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014.
Client expense: Not reported · Firm income: $30,000
2015 · third_quarter · Medicare/Medicaid
Medicare Coverage and Reimbursement issues; Medicare access to DXA services; Medicare reimbursement for antimicrobial drugs, including related provisions in HR 512, The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014.
Client expense: Not reported · Firm income: $30,000
2015 · third_quarter · Medicare/Medicaid
H.R. 2581 Preservation of Access for Seniors in Medicare Advantage Act of 2015 Provisions related to changes to the Medicare Advantage Program H.R. 2570 Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015Provisions related to changes to the Medicare Advantage Program H.R. 1190 H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 Provisions related to IPAB repeal S. 1369Value-Based Insurance Design Seniors Copayment Reduction Act of 2015 Provisions related to changes to the Medicare Advantage Program S. 1083 Medicare Drug Savings Act of 2015 S. 141 Protecting Seniors' Access to Medicare Act of 2015 Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 31 Medicare Prescription Drug Price Negotiation Act of 2015 Provisions related to Secretary negotiation authority in Part D program H.R. 1190 Protecting Seniors' Access to Medicare Act of 2013provisions related to the Independent Payment Advisory Board H.R. 1470 SGR Repeal and Medicare Provider Payment Modernization Act of 2015Provisions related to SGR reform H.R. 4187 Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) S. 31Medicare Prescription Drug Price Negotiation Act of 2013provisions related to Part D issues S. 141Protecting Seniors' Access to Medicare Act of 2013provisions related to the Independent Payment Advisory Board S. 648Medicare Formulary Improvement Actprovisions related to Medicare Part D No bill # assignedProposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy No bill # assignedIssues related to better use of medicines and comprehensive medication management No bill # assignedVaccine access and coverage issues HR. 512 - the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 S. 2055 - the Medical Countermeasure Innovation Act of 2015
| Democratic |
| GU |
| Michael M. Honda | Democratic | CA |
| Raúl M. Grijalva | Democratic | AZ |
Client expense: $1,490,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S.
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $380,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $842,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office